Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) shot up 5.5% on Tuesday . The company traded as high as $3.65 and last traded at $3.64. 117,090 shares traded hands during trading, an increase of 83% from the average session volume of 63,849 shares. The stock had previously closed at $3.45.
Avenue Therapeutics Stock Up 5.5 %
The firm has a market cap of $3.42 million, a PE ratio of -0.46 and a beta of -0.19. The business has a 50-day moving average price of $3.55 and a two-hundred day moving average price of $7.92.
Avenue Therapeutics (NASDAQ:ATXI – Get Free Report) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($15.40) EPS for the quarter.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.
Featured Articles
- Five stocks we like better than Avenue Therapeutics
- Dividend Payout Ratio Calculator
- ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
- Investing In Preferred Stock vs. Common Stock
- Leading Beverage Company’s Stock Bubbles Higher: Rally Ahead
- Consumer Staples Stocks, Explained
- Can This Meme Stock Stage One Last Rally?
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
